-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure 3: Example of direct thrombin inhibitor monitoring test values over time in patients taking a constant dose of
argatroban.
A, diluted thrombin time (dTT).
B, activated partial thromboplastin time (aPTT).
The patient is a 7-month-old man taking argatroban for venous thrombosis in the setting of heparin-induced thrombocytopenia
.
As shown, the dose of argatroban was constant at 2.
25 μ g/kg/min
during monitoring.
Figure 4: Determination of mean Pearson coefficient for diluted thrombin time (dTT) or activated partial thromboplastin time (aPTT) compared to bivaludin or argatroban
.
A, for argatroban, dTT had a significantly higher mean correlation (r2) dose greater than aPTT (n = 10, P = .
028, one-tailed paired t-test).
B.
When agatroban and bivalutin were combined, the mean correlation of dTT was significantly higher than that of the control group (r2) at doses greater than aPTT (n = 14, P = .
007, single-tailed paired t-test).
Original source:
Hasan RA, Pak J, Kirk CJ, Friedland-Little JM, Chandler WL.
Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients [published online ahead of print, 2022 Nov 9].
Am J Clin Pathol.
2022; aqac131.
doi:10.
1093/ajcp/aqac131